SCHEMBL540900

SCHEMBL540900

CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(=O)CN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.47
CA1 P00915 4/20 0.47
CA9 Q16790 3/20 0.47
CA2 P00918 2/20 0.47
MGLL Q99685 1/20 0.42
ZDHHC20 Q5W0Z9 2/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42
CA4 P22748 1/20 0.41
DNM1 Q05193 4/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
MMP8 P22894 1/20 0.41
CES2 O00748 3/20 0.39
CES1 P23141 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1557690 1.00 CA12 (0.47) CA12CA1CA9CA2MGLL
SCHEMBL31496780 1.00 CA12 (0.47) CA12CA1CA9CA2MGLL
SCHEMBL4210960 1.00 CA12 (0.47) CA12CA1CA9CA2MGLL
SCHEMBL6386826 1.00 CA12 (0.47) CA12CA1CA9CA2MGLL
SCHEMBL28201517 0.92 MGLL (0.48) CA12CA1CA9CA2MGLL
SCHEMBL4577559 0.91 CA12 (0.52) CA12CA1CA9CA2MMP1
SCHEMBL4795873 0.89 FAAH (0.53) MMP2KDM4ECYP1A2CYP3A4CYP2C19
SCHEMBL3486719 0.89 FAAH (0.53) MMP2KDM4ECYP1A2CYP3A4CYP2C19
SCHEMBL3423879 0.87 GPR84 (0.41) CA12CA1CA9CA2ZDHHC20
SCHEMBL28770693 0.85 GRIK1 (0.51) CA2ZDHHC20ZDHHC2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4351533-A1 APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF Generation Bio Co. (US) 2024-04-17 EP claimed
WO-2023239756-A1 LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF GENERATION BIO CO. (US) 2023-12-14 WO claimed
WO-2022261101-A1 APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF GENERATION BIO CO. (US) 2022-12-15 WO claimed
EP-4709361-A1 A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF Agency for Science, Technology and Research (SG) 2026-03-18 EP disclosed
WO-2025090023-A1 A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND, AND RELATED METHODS THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-05-01 WO disclosed
WO-2025080209-A1 A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-04-17 WO disclosed
WO-2025048714-A1 A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-03-06 WO disclosed
WO-2024232832-A1 A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2024-11-14 WO disclosed
WO-2024138189-A2 METHODS FOR ANALYZING NUCLEIC ACID CARGOS OF LIPID NUCLEIC ACID ASSEMBLIES INTELLIA THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
EP-4380576-A2 COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY Verve Therapeutics, Inc. (US) 2024-06-12 EP disclosed
WO-2024107765-A2 COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES REGENERON PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
EP-2104740-A2 LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES Sirna Therapeutics, Inc. (US) 2009-09-30 EP disclosed
US-7553830-B2 Compositions for the delivery of negatively charged molecules SIRNA THERAPEUTICS, INC. (US) 2009-06-30 US disclosed
WO-2008147438-A2 LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES SIRNA THERAPEUTICS, INC. (US) 2008-12-04 WO disclosed
WO-2008103276-A2 COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES MERCK & CO., INC. (US) 2008-08-28 WO disclosed
EP-1922300-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM Sirna Therapeutics Inc. (US) 2008-05-21 EP disclosed
WO-2007086883-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM SIRNA THERAPEUTICS, INC. (US) 2007-08-02 WO disclosed
WO-2007086881-A2 CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM SIRNA THERAPEUTICS, INC. (US) 2007-08-02 WO disclosed
EP-1068188-A1 NOVEL NUCLEIC ACID TRANSFER AGENTS, COMPOSITIONS CONTAINING SAME AND USES Aventis Pharma S.A. (FR) 2001-01-17 EP disclosed
WO-1999051581-A1 NOVEL NUCLEIC ACID TRANSFER AGENTS, COMPOSITIONS CONTAINING SAME AND USES AVENTIS PHARMA S.A. (FR) 1999-10-14 WO disclosed